Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.87 |
| ▸ | ELOC | Q15369 | 7/20 | 0.65 |
| ▸ | ELOB | Q15370 | 7/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27164784 | 1.00 | VHL (0.87) | VHLELOCELOB | |
| SCHEMBL18530348 | 1.00 | VHL (0.87) | VHLELOCELOB | |
| SCHEMBL27378000 | 1.00 | VHL (0.87) | VHLELOCELOB | |
| SCHEMBL18063740 | 0.93 | VHL (1.00) | VHLELOCELOB | |
| SCHEMBL18063891 | 0.93 | VHL (1.00) | VHLELOCELOB | |
| SCHEMBL18063917 | 0.93 | VHL (1.00) | VHLELOCELOB | |
| SCHEMBL18551386 | 0.93 | VHL (1.00) | VHLELOCELOB | |
| SCHEMBL23602167 | 0.92 | VHL (0.86) | VHLELOCELOB | |
| SCHEMBL23602530 | 0.92 | VHL (0.86) | VHLELOCELOB | |
| SCHEMBL25653934 | 0.92 | VHL (0.86) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109138-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4259144-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109138-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | VHL 264/4885ELOC 628/4885ELOB 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.